Abiopharma

🔍 Vyvoda Michael (Executive)

Company: Enovix Corp (ENVX)

Report Date: 2026-08-05

Detailed Transactions and Holdings:

• Acquired 932,400 shares of Common Stock (Direct)
  Date: 2026-08-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 932,400.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 23,310 shares of Common Stock (Direct)
  Date: 2026-08-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 955,710.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 13,579 shares of Common Stock at $4.29 per share (Direct)
  Date: 2026-08-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 942,131.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: Reflects shares issuable upon the settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on the one-year anniversary of the vesting commencement date (August 5, 2026) and the remaining balance will vest in 12 equal quarterly installments each quarter thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
• F2: Represents shares of the Issuer's common stock issued to the Reporting Person upon the receipt of a fully vested award of RSUs on August 5, 2026.
• F3: Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the immediate vesting of RSUs.
• F4: Includes 932,400 shares issuable upon the settlement of RSUs granted to the Reporting Person.